Simultaneous Assessment of the In Vivo Amount of CYP1A2 and CYP3A2 by the PKCYP-test Using Theophylline in Rats

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 3, 2002, Pages 190-198

  Matsunaga, Noriko ^a   Hayashi, Miyoko ^a   Yamamoto, Keiko ^a   Nishijima, Taeko ^a   Nakashima, Emi ^a   Kizu, Junko ^b   Nishihara, Kazuyo ^c   Morikawa, Akinobu ^d  

^a Department of Pharmaceutics ^*  (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Nippon Express Hlth Ins Society   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

CYP1A2; CYP3A2; physiologically based pharmacokinetic model; PKCYP test; theophylline

Indexed keywords

EID: 33646513196     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.190     Document Type: Article

References (26)

1. Streetman, D. S., Bertino, J. J. and Nafziger, A. N.: Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 10: 187-216 (2000).
2. Rodrigues, A. D.: Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol., 57: 465-480 (1999).
3. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A. and Sugiyama, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73: 147-171 (1997).
4. Suzuki, H., Iwatsubo, T. and Sugiyama, Y.: Applications and prospects for physiologically-based Pharmacokinetic (PB-PK) models involving pharmaceutical agents. Toxicol. Lett., 83: 349-355 (1995).
5. Obach, R. S.: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 27: 1350-1359 (1999).
6. Matsunaga, N., Hattori, K., Iizasa, H., Fukuhara, M., Takanaka, A. and Nakashima, E.: A simplified diagnostic approach for estimating in vivo hepatic drug clearance; its preliminary application for the drug caffeine, using CYP1A probe in a rat model. Jpn. J. Hosp. Pharm., 26: 492-504 (2000).
7. Matsunaga, N., Hattori, K., Iizasa, H., Kizu, J., Takanaka, A. and Nakashima, E.: Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease. Biol. Pharm. Bull., 24: 1037-1043 (2001).
8. Matsunaga, N., Nishijima, T., Hattori, K., Iizasa, H., Yamamoto, K., Kizu, J., Takanaka, A., Morikawa, A. and Nakashima, E.: Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe. Biol. Pharm. Bull., 24: 1305-1310 (2001).
9. Williams, J. F., Lowitt, S. and Szentivanyi, A.: Effects of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophylline and its metabolites in rats. Biochem. Pharmacol., 28: 2935-2940 (1979).
10. McManus, M. E., Miners, J. O., Gregor, D., Stupans, I. and Birkett, D. J.: Theophylline metabolism by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450. J. Pharm. Pharmacol., 40: 388-391 (1988).
11. Sun, B., Fukuhara, M. and Takanaka, A.: Characterization of benzo[a]pyrene metabolism and related cytochrome P-450 isozymes in Syrian hamster livers. J. Toxicol. Environ. Health., 46: 47-55 (1995).
12. Apseloff, G., Shepard, D. R., Chambers, M. A., Nawoot, S., Mays, D. C. and Gerber, N.: Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. Drug Metab. Dispos., 18: 298-303 (1990).
13. Krul, C. and Hageman, G.: Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl., 709: 27-34 (1998).
14. Nakashima, E., Yokogawa, K., Ichimura, F., Hashimoto, T., Yamana, T. and Tsuji, A.: Effects of fasting on biperiden pharmacokinetics in the rat. J. Pharm. Sci., 76: 10-13 (1987).
15. Bischoff, K. B., Dedrick, R. L., Zaharko, D. S. and Longstreth, J. A.: Methotrexate pharmacokinetics. J. Pharm. Sci., 60: 1128-1133 (1971).
16. Montandon, B., Roberts, R. J. and Fischer, L. J.: Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J. Pharmacokinet. Biopharm., 3: 277-290 (1975).
17. Kawai, R., Lemaire, M., Steimer, J. L., Bruelisauer, A., Niederberger, W. and Rowland, M.: Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J. Pharmacokinet. Biopharm., 22: 327-365 (1994).
18. Gabrielsson, J. L., Paalzow, L. K. and Nordstrom, L.: A physiologically based pharmacokinetic model for theophylline disposition in the pregnant and nonpregnant rat. J. Pharmacokinet. Biopharm., 12: 149-165 (1984).
19. Nakashima, E., Yokogawa, K., Ichimura, F., Kurata, K., Kido, H., Yamaguchi, N. and Yamana, T.: A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans. Chem. Pharm. Bull (Tokyo)., 35: 718-725 (1987).
20. Yamaoka, K., Nakagawa, T. and Uno, T.: Moment analysis for disposition kinetics of several cephalosporin antibiotics in rats. J. Pharm. Pharmacol., 35: 19-22 (1983).
21. Fuhr, U., Doehmer, J., Battula, N., Wolfel, C., Kudla, C., Keita, Y. and Staib, A. H.: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol., 43: 225-235 (1992).
22. Soucek, P. and Gut, I.: Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica, 22: 83-103 (1992).
23. Venkatakrishnan, K., von, M. L. and Greenblatt, D. J.: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther., 297: 326-337 (2001).
24. Carlile, D. J., Hakooz, N., Bayliss, M. K. and Houston, J. B.: Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharmacol., 47: 625-635 (1999).
25. Houston, J. B.: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 47: 1469-1479 (1994).
26. Gorodischer, R., Yaari, A., Margalith, M., Warszawski, D. and Ben, Z. Z.: Changes in theophylline metabolism during postnatal development in rat liver slices. Biochem. Pharmacol., 35: 3077-3081 (1986).